新闻源 财富源

2019年10月18日 星期五

康缘药业(600557)公告正文

康缘药业:2016年第一季度报告

公告日期:2016-04-26

    江苏康缘药业股份有限公司(股票代码:600557)            2016 年第一季度报告



公司代码:600557                                         公司简称:康缘药业




                   江苏康缘药业股份有限公司
                     2016 年第一季度报告




                           二〇一六 年 四 月 二十五 日
                                             1 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                    2016 年第一季度报告




                                          目录
一、重要提示...................................................................... 3

二、公司主要财务数据和股东变化 .................................................... 3

三、重要事项...................................................................... 5

四、附录.......................................................................... 9




                                             2 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                               2016 年第一季度报告




一、       重要提示

1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,
    不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。



1.2 公司全体董事出席董事会审议季度报告。


1.3 公司负责人肖伟、主管会计工作负责人尹洪刚 及会计机构负责人(会计主管人员)江锁成保
    证季度报告中财务报表的真实、准确、完整。


1.4 本公司第一季度报告未经审计。



二、       公司主要财务数据和股东变化

2.1 主要财务数据

                                                                         单位:元 币种:人民币
                                                                               本报告期末比上年
                                     本报告期末              上年度末
                                                                                 度末增减(%)
总资产                            4,355,957,768.47        4,304,503,018.18                    1.20
归属于上市公司股东的净资产        2,893,000,375.47        2,810,636,242.02                    2.93
                                   年初至报告期末         上年初至上年报告
                                                                               比上年同期增减(%)
                                     (1-3 月)             期末(1-3 月)
经营活动产生的现金流量净额           137,589,323.00         137,637,241.14                   -0.03
                                   年初至报告期末         上年初至上年报告
                                                                               比上年同期增减(%)
                                     (1-3 月)             期末(1-3 月)
营业收入                             698,297,664.70         658,029,406.40                    6.12
归属于上市公司股东的净利润            82,365,842.77          81,617,680.53                    0.92
归属于上市公司股东的扣除非
                                      80,065,470.38          79,790,293.62                    0.34
经常性损益的净利润
加权平均净资产收益率(%)                          2.89                 3.21   减少 0.32 个百分点
基本每股收益(元/股)                              0.16                 0.16                         0
稀释每股收益(元/股)                              0.16                 0.16                         0


非经常性损益项目和金额
√适用 □不适用
                                                                         单位:元 币种:人民币
                              项目                                             本期金额
非流动资产处置损益                                                                    -35,973.46
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合
                                                                                      740,778.37
国家政策规定、按照一定标准定额或定量持续享受的政府补助除外
                                             3 / 22
       江苏康缘药业股份有限公司(股票代码:600557)                                        2016 年第一季度报告



除上述各项之外的其他营业外收入和支出                                                             2,018,880.00
少数股东权益影响额(税后)                                                                          -9,193.95
所得税影响额                                                                                      -414,118.57
                                 合计                                                            2,300,372.39


2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表

                                                                                                     单位:股
                 股东总数(户)                                                                        28,343
                                             前十名股东持股情况
                                                       持有有限售           质押或冻结情况
                                期末持股       比例
       股东名称(全称)                                条件股份数                                    股东性质
                                  数量          (%)                     股份状态          数量
                                                              量
                                                                                                    境内非国有
江苏康缘集团有限责任公司       141,180,385     27.48   135,224,737          无
                                                                                                       法人
连云港康贝尔医疗器械有限                                                                            境内非国有
                                26,558,806      5.17                       质押      26,000,000
公司                                                                                                   法人
中国工商银行股份有限公司
-东方红中国优势灵活配置        17,134,700      3.34                       未知                        其他
混合型证券投资基金
中央汇金资产管理有限责任
                                15,233,400      2.97                       未知                        其他
公司
萧伟                            14,169,699      2.76                        无                      境内自然人
汇添富基金-工商银行-汇
                                9,954,330       1.94        9,954,330      未知                        其他
添富-康缘资产管理计划
中欧基金-农业银行-中欧
                                4,532,900       0.88                       未知                        其他
中证金融资产管理计划
易方达基金-农业银行-易
                                4,532,900       0.88                       未知                        其他
方达中证金融资产管理计划
嘉实基金-农业银行-嘉实
                                4,532,900       0.88                       未知                        其他
中证金融资产管理计划
工银瑞信基金-农业银行-
工银瑞信中证金融资产管理        4,532,900       0.88                       未知                        其他
计划
大成基金-农业银行-大成
                                4,532,900       0.88                       未知                        其他
中证金融资产管理计划
博时基金-农业银行-博时
                                4,532,900       0.88                       未知                        其他
中证金融资产管理计划
                                     前十名无限售条件股东持股情况
                                               持有无限售条件流通股的                股份种类及数量
                  股东名称
                                                        数量                       种类               数量
连云港康贝尔医疗器械有限公司                                  26,558,806     人民币普通股           26,558,806



                                                   4 / 22
       江苏康缘药业股份有限公司(股票代码:600557)                              2016 年第一季度报告



中国工商银行股份有限公司-东方红中国优
                                                         17,134,700    人民币普通股      17,134,700
势灵活配置混合型证券投资基金
中央汇金资产管理有限责任公司                             15,233,400    人民币普通股      15,233,400
萧伟                                                     14,169,699    人民币普通股      14,169,699
江苏康缘集团有限责任公司                                  5,955,648    人民币普通股        5,955,648
中欧基金-农业银行-中欧中证金融资产管
                                                          4,532,900    人民币普通股        4,532,900
理计划
易方达基金-农业银行-易方达中证金融资
                                                          4,532,900    人民币普通股        4,532,900
产管理计划
嘉实基金-农业银行-嘉实中证金融资产管
                                                          4,532,900    人民币普通股        4,532,900
理计划
工银瑞信基金-农业银行-工银瑞信中证金
                                                          4,532,900    人民币普通股        4,532,900
融资产管理计划
大成基金-农业银行-大成中证金融资产管
                                                          4,532,900    人民币普通股        4,532,900
理计划
博时基金-农业银行-博时中证金融资产管
                                                          4,532,900    人民币普通股        4,532,900
理计划
                                                前十大股东中,江苏康缘集团有限责任公司和肖伟先生存在
                                            关联关系,肖伟先生为江苏康缘集团有限责任公司第一大股东;
                                            汇添富基金-工商银行-汇添富-康缘资产管理计划为江苏康
上述股东关联关系或一致行动的说明            缘集团有限责任公司一致行动人。公司未知其他股东之间、其他
                                            股东与前十名无限售条件股东之间是否存在关联关系或一致行
                                            动人关系;公司未知其他前十名无限售条件股东之间是否存在关
                                            联关系或一致行动人关系。



2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情
    况表

□适用 √不适用

三、       重要事项

3.1 公司主要会计报表项目、财务指标重大变动的情况及原因

√适用 □不适用
       3.1.1 截至报告期末,公司资产负债表项目大幅变动的原因分析
                                                                         单位:元     币种:人民币
                                                            变动比
       项目名称         本期期末数         本期期初数                           情况说明
                                                            例(%)
                                                                       主要系本期末未到期票据较
 应收票据             477,750,469.17     709,374,910.40      -32.65
                                                                       期初减少所致
                                                                       主要系报告期内新增预付技
 预付款项              73,089,809.97      28,675,087.40      154.89
                                                                       术转让款所致
 其他流动资产           4,650,000.00      10,853,684.83      -57.16    主要系本期末理财产品较期

                                                5 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                              2016 年第一季度报告



                                                                    初减少所致
                                                                    主要系本期末未决算工程较
在建工程           135,808,461.99      92,325,802.64      47.10
                                                                    期初增加所致
                                                                    主要系报告期内研究院改造
长期待摊费用         7,047,546.96        4,453,980.08     58.23
                                                                    计入长期待摊费用所致
                                                                    主要系本期末预付工程款较
其他非流动资产      96,978,556.53      32,386,759.10     199.44
                                                                    期初增加所致
                                                                    主要系报告期内应付票据到
应付票据                          0    86,900,000.00     -100.00
                                                                    期所致
                                                                    主要系本期末新增客户预付
预收款项            60,988,199.55      43,498,425.96      40.21
                                                                    款项较期初增加所致
                                                                    主要系报告期内支付年底计
应付职工薪酬         4,180,645.37        7,205,285.50    -41.98
                                                                    提调薪所致
                                                                    主要系报告期内部分贷款利
应付利息             2,370,816.95        1,661,531.18     42.69
                                                                    息支付方式为年付所致
                                                                    主要系本期末将“长期借
长期借款                       0.00    45,000,000.00     -100.00    款”重分类到“1 年内到期的
                                                                    非流动负债”所致

    3.1.2 截至报告期末,公司利润表项目大幅变动的原因分析

                                                                   单位:元   币种:人民币
                                           去年同期     变动比例
       项目名称             本期金额                                          情况说明
                                             金额         (%)
                                                                     主要系报告期内处置固定资
营业外支出                   35,973.46         125.00   28678.77
                                                                     产较去年同期增长所致
归属母公司所有者的其                                                 主要系报告期内外币报表折
                             -1,709.32       7,440.98    -122.97
他综合收益的税后净额                                                 算差额较去年同期减少所致
                                                                     主要系报告期内非全资子公
归属于少数股东的综合
                            556,640.15    281,068.04       98.04     司净利润较去年同期增加所
收益总额
                                                                     致

    3.1.3 截至报告期末,公司现金流量表项目大幅变动的原因分析

                                                                   单位:元   币种:人民币
                                          去年同期        变动比例
    项目名称          本期金额                                                 情况说明
                                            金额            (%)
筹资活动产生的                                                         主要系去年同期偿还银行
                    28,045,311.19      -201,862,218.88      不适用
现金流量净额                                                           借款远高于新增借款所致



3.2 重要事项进展情况及其影响和解决方案的分析说明

√适用 □不适用

   1、关于公司董事、高级管理人员及核心人员增持的情况说明
                                             6 / 22
      江苏康缘药业股份有限公司(股票代码:600557)                                2016 年第一季度报告



    2016年3月15日,公司接到连云港康瑞企业管理合伙企业(有限合伙)(以下简称“康瑞合伙
企业”)的通知,康瑞合伙企业通过上海证券交易所交易系统增持了公司100,000股,占公司总股
本的0.02%。公司实际控制人肖伟先生持有康瑞合伙企业40%份额,系康瑞合伙企业普通合伙人、
执行事务合伙人,本次增持完成后,肖伟先生与其实际控制的康瑞合伙企业、康缘集团、康缘集
团一致行动人“华康资产管理计划”“汇康资产管理计划”合计持有公司股份168,092,780股,占
公司总股本32.72%。肖伟先生仍为公司实际控制人。(详见2016 年3月16日及3月18日刊登于上海
证券交易所网站 www.sse.com.cn、《中国证券报》、《上海证券报》公告)。

      2、报告期内募集资金存放及使用情况的说明

    公司募集资金已于2015年度内使用完毕,详见公司于2016年4月16日在上海证券交易所网站
(www.sse.com.cn)上刊登的《关于公司募集资金存放与实际使用情况的专项报告》。截至2016
年3月31日,募集资金存储专户内余额为18.28万元。



3.3 公司及持股 5%以上的股东承诺事项履行情况

√适用 □不适用

                                                                                          是否   是否
承诺     承诺                                                                 承诺时间    有履   及时
                 承诺方                        承诺内容
背景     类型                                                                  及期限     行期   严格
                                                                                           限    履行



                          公司控股股东江苏康缘集团有限责任公司在与本公司      承诺时间
与再
                 江苏康   签署的《避免同业竞争股东协议书》中郑重承诺:目前, 为 2007 年
融资     解决
                 缘集团   公司所有业务,康缘集团及其控股和实际控制下的其他     7 月 10
相关     同业                                                                              否     是
                 有限责   企业均不涉及。康缘集团及其控股和实际控制下的其他    日,本承
的承     竞争
                 任公司   企业与本公司及本公司控股、实际控制的企业间不存在    诺长期有
 诺
                          同业竞争的情形。                                       效




                          江苏康缘集团有限责任公司将尽量减少与本公司之间
                          的关联交易。对于无法避免的任何业务往来或交易均应
                                                                              承诺时间
与再                      按照公平、公允和等价有偿的原则进行,交易价格应按
                 江苏康                                                      为 2007 年
融资     解决             市场公认的合理价格确定,并按规定履行信息披露义
                 缘集团                                                        7 月 10
相关     关联             务。康缘集团及其控股和实际控制下的其他企业与本公                 否     是
                 有限责                                                       日,本承
的承     交易             司及本公司控股和实际控制下的其他企业就相互间关
                 任公司                                                       诺长期有
 诺                       联事务及交易所做出的任何约定及安排,均不妨碍对方
                                                                                 效
                          为其自身利益、在市场同等竞争条件下与任何第三方进
                          行业务往来或交易。




                                                7 / 22
      江苏康缘药业股份有限公司(股票代码:600557)                              2016 年第一季度报告


与再                                                                       2014 年 12
                 江苏康
融资                                                                        月 22 日
         股份    缘集团   康缘集团承诺认购本次发行的股票自发行结束之日起
相关                                                                        -2017 年     是    是
         限售    有限责   36 个月内不上市交易或转让。
的承                                                                        12 月 21
                 任公司
 诺                                                                            日



3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的
    警示及原因说明

□适用 √不适用


                                                     公司名称       江苏康缘药业股份有限公司
                                                     法定代表人     肖伟
                                                     日期           2016 年 4 月 25 日




                                               8 / 22
      江苏康缘药业股份有限公司(股票代码:600557)                          2016 年第一季度报告




四、         附录

4.1    财务报表

                                          合并资产负债表
                                         2016 年 3 月 31 日
编制单位:江苏康缘药业股份有限公司
                                                     单位:元 币种:人民币 审计类型:未经审计
                    项目                             期末余额               年初余额
流动资产:
      货币资金                                         209,612,288.40         221,716,287.08
      结算备付金
      拆出资金
    以公允价值计量且其变动计入当
期损益的金融资产
      衍生金融资产
      应收票据                                         477,750,469.17         709,374,910.40
      应收账款                                       1,125,545,798.20         956,309,810.30
      预付款项                                          73,089,809.97          28,675,087.40
      应收保费
      应收分保账款
      应收分保合同准备金
      应收利息
      应收股利
      其他应收款                                        47,824,213.19          50,786,318.62
      买入返售金融资产
      存货                                             198,791,818.08         187,850,105.20
      划分为持有待售的资产
      一年内到期的非流动资产
      其他流动资产                                       4,650,000.00          10,853,684.83
        流动资产合计                                 2,137,264,397.01       2,165,566,203.83
非流动资产:
      发放贷款和垫款
      可供出售金融资产
      持有至到期投资
      长期应收款
      长期股权投资                                       3,978,529.97           3,978,529.97
      投资性房地产
      固定资产                                       1,594,430,020.83       1,622,791,154.66
      在建工程                                         135,808,461.99          92,325,802.64
      工程物资
      固定资产清理

                                               9 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                      2016 年第一季度报告



   生产性生物资产
   油气资产
   无形资产                                          293,350,256.15     295,929,763.23
   开发支出                                           18,000,000.00      18,000,000.00
   商誉                                               58,988,858.14      58,988,858.14
   长期待摊费用                                        7,047,546.96       4,453,980.08
   递延所得税资产                                     10,111,140.89      10,081,966.53
   其他非流动资产                                     96,978,556.53      32,386,759.10
      非流动资产合计                               2,218,693,371.46   2,138,936,814.35
        资产总计                                   4,355,957,768.47   4,304,503,018.18
流动负债:
   短期借款                                          403,000,000.00     343,000,000.00
   向中央银行借款
   吸收存款及同业存放
   拆入资金
    以公允价值计量且其变动计入当
期损益的金融负债
   衍生金融负债
   应付票据                                                    0.00      86,900,000.00
   应付账款                                          259,007,399.21     253,566,639.80
   预收款项                                           60,988,199.55      43,498,425.96
   卖出回购金融资产款
   应付手续费及佣金
   应付职工薪酬                                        4,180,645.37       7,205,285.50
   应交税费                                           87,961,169.50      75,075,683.26
   应付利息                                            2,370,816.95       1,661,531.18
   应付股利                                               24,375.00           24,375.00
   其他应付款                                        380,200,759.05     393,885,068.87
   应付分保账款
   保险合同准备金
   代理买卖证券款
   代理承销证券款
   划分为持有待售的负债
   一年内到期的非流动负债                            100,000,000.00      80,000,000.00
   其他流动负债
      流动负债合计                                 1,297,733,364.63   1,284,817,009.57
非流动负债:
   长期借款                                                    0.00      45,000,000.00
   应付债券
   其中:优先股
          永续债
   长期应付款
                                            10 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                             2016 年第一季度报告



   长期应付职工薪酬
   专项应付款                                          2,686,995.00              2,353,672.00
   预计负债
   递延收益                                          101,869,728.55            101,585,429.92
   递延所得税负债
   其他非流动负债
      非流动负债合计                                 104,556,723.55            148,939,101.92
        负债合计                                   1,402,290,088.18         1,433,756,111.49
所有者权益
   股本                                              513,707,601.00            513,707,601.00
   其他权益工具
   其中:优先股
          永续债
   资本公积                                          520,433,141.68            520,433,141.68
   减:库存股
   其他综合收益                                         -221,050.78                -219,341.46
   专项储备
   盈余公积                                          237,552,889.89            237,552,889.89
   一般风险准备
   未分配利润                                      1,621,527,793.68          1,539,161,950.91
   归属于母公司所有者权益合计                      2,893,000,375.47          2,810,636,242.02
   少数股东权益                                       60,667,304.82             60,110,664.67
      所有者权益合计                               2,953,667,680.29         2,870,746,906.69
        负债和所有者权益总计                       4,355,957,768.47         4,304,503,018.18



法定代表人:肖伟            主管会计工作负责人:尹洪刚                会计机构负责人:江锁成




                                            11 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                         2016 年第一季度报告



                                      母公司资产负债表
                                      2016 年 3 月 31 日
编制单位:江苏康缘药业股份有限公司
                                                   单位:元 币种:人民币 审计类型:未经审计
                 项目                               期末余额              年初余额
流动资产:
  货币资金                                            155,107,299.10       164,310,146.60
  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据                                            393,904,367.72       629,712,906.75
  应收账款                                         1,002,792,579.68        827,238,807.78
  预付款项                                             64,561,599.23        22,696,079.01
  应收利息
  应收股利                                              4,759,107.34         4,759,107.34
  其他应收款                                          272,398,699.04       251,689,188.08
  存货                                                175,204,426.54       163,064,614.72
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产
    流动资产合计                                   2,068,728,078.65      2,063,470,850.28
非流动资产:
  可供出售金融资产
  持有至到期投资
  长期应收款
  长期股权投资                                        191,802,812.64       189,532,612.64
  投资性房地产
  固定资产                                         1,347,777,470.88      1,375,363,472.18
  在建工程                                             74,655,082.09        43,025,950.72
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                            225,283,235.87       226,884,874.59
  开发支出                                             18,000,000.00        18,000,000.00
  商誉
  长期待摊费用                                          6,124,127.50         3,457,147.23
  递延所得税资产                                        4,058,388.82         5,977,513.48
  其他非流动资产                                       85,041,623.32        19,699,254.78
    非流动资产合计                                 1,952,742,741.12      1,881,940,825.62
      资产总计                                     4,021,470,819.77      3,945,411,675.90
流动负债:

                                            12 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                       2016 年第一季度报告



 短期借款                                             343,000,000.00     283,000,000.00
  以公允价值计量且其变动计入当期损
益的金融负债
 衍生金融负债
 应付票据                                                      0.00       86,900,000.00
 应付账款                                             214,768,582.95     192,880,487.28
 预收款项                                              33,446,796.89      18,505,611.15
 应付职工薪酬                                           2,209,292.27       4,610,831.32
 应交税费                                              80,499,717.29      63,923,402.50
 应付利息                                                901,372.50           657,197.84
 应付股利
 其他应付款                                           295,245,240.98     313,867,062.13
 划分为持有待售的负债
 一年内到期的非流动负债                               100,000,000.00      80,000,000.00
 其他流动负债
   流动负债合计                                    1,070,071,002.88    1,044,344,592.22
非流动负债:
 长期借款                                                      0.00       45,000,000.00
 应付债券
 其中:优先股
        永续债
 长期应付款
 长期应付职工薪酬
 专项应付款                                             2,353,672.00       2,353,672.00
 预计负债
 递延收益                                              78,914,464.66      78,244,064.66
 递延所得税负债
 其他非流动负债
   非流动负债合计                                     81,268,136.66      125,597,736.66
      负债合计                                     1,151,339,139.54    1,169,942,328.88
所有者权益:
 股本                                                 513,707,601.00     513,707,601.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                             520,570,073.21     520,570,073.21
 减:库存股
 其他综合收益
 专项储备
 盈余公积                                             235,745,729.33     235,745,729.33
 未分配利润                                        1,600,108,276.69    1,505,445,943.48
   所有者权益合计                                  2,870,131,680.23    2,775,469,347.02
                                            13 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                             2016 年第一季度报告



      负债和所有者权益总计                         4,021,470,819.77         3,945,411,675.90



法定代表人:肖伟            主管会计工作负责人:尹洪刚                会计机构负责人:江锁成




                                            14 / 22
     江苏康缘药业股份有限公司(股票代码:600557)                            2016 年第一季度报告



                                           合并利润表
                                         2016 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                     项目                           本期金额(1-3 月)     上期金额(1-3 月)
一、营业总收入                                          698,297,664.70         658,029,406.40
其中:营业收入                                          698,297,664.70         658,029,406.40
       利息收入
       已赚保费
       手续费及佣金收入
二、营业总成本                                          602,942,963.61         562,968,696.13
其中:营业成本                                          192,270,597.44         173,390,103.13
       利息支出
       手续费及佣金支出
       退保金
       赔付支出净额
       提取保险合同准备金净额
       保单红利支出
       分保费用
       营业税金及附加                                      11,442,302.03        10,473,146.25
       销售费用                                         286,966,927.63         269,474,230.27
       管理费用                                            99,115,343.10        94,923,190.82
       财务费用                                            12,858,600.98        14,426,756.00
       资产减值损失                                           289,192.43            281,269.66
  加:公允价值变动收益(损失以“-”号填
列)
       投资收益(损失以“-”号填列)
       其中:对联营企业和合营企业的投资收

       汇兑收益(损失以“-”号填列)
三、营业利润(亏损以“-”号填列)                         95,354,701.09        95,060,710.27
  加:营业外收入                                            2,759,658.37         2,150,000.00
       其中:非流动资产处置利得
  减:营业外支出                                               35,973.46                125.00
       其中:非流动资产处置损失
四、利润总额(亏损总额以“-”号填列)                     98,078,386.00        97,210,585.27
  减:所得税费用                                           15,155,903.08        15,311,836.70
五、净利润(净亏损以“-”号填列)                         82,922,482.92        81,898,748.57
  归属于母公司所有者的净利润                               82,365,842.77        81,617,680.53
  少数股东损益                                                556,640.15            281,068.04
六、其他综合收益的税后净额                                    -1,709.32               7,440.98
  归属母公司所有者的其他综合收益的税后净                       -1,709.32              7,440.98
                                             15 / 22
     江苏康缘药业股份有限公司(股票代码:600557)                        2016 年第一季度报告




    (一)以后不能重分类进损益的其他综合
收益
      1.重新计量设定受益计划净负债或净资
产的变动
      2.权益法下在被投资单位不能重分类进
损益的其他综合收益中享有的份额
     (二)以后将重分类进损益的其他综合收
                                                           -1,709.32              7,440.98

      1.权益法下在被投资单位以后将重分类
进损益的其他综合收益中享有的份额
       2.可供出售金融资产公允价值变动损益
      3.持有至到期投资重分类为可供出售金
融资产损益
       4.现金流量套期损益的有效部分
       5.外币财务报表折算差额                              -1,709.32              7,440.98
       6.其他
  归属于少数股东的其他综合收益的税后净额
七、综合收益总额                                       82,920,773.60        81,906,189.55
  归属于母公司所有者的综合收益总额                     82,364,133.45        81,625,121.51
  归属于少数股东的综合收益总额                            556,640.15            281,068.04
八、每股收益:
  (一)基本每股收益(元/股)                                     0.16                   0.16
  (二)稀释每股收益(元/股)                                     0.16                   0.16



法定代表人:肖伟             主管会计工作负责人:尹洪刚           会计机构负责人:江锁成




                                             16 / 22
     江苏康缘药业股份有限公司(股票代码:600557)                           2016 年第一季度报告



                                          母公司利润表
                                         2016 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                                    单位:元 币种:人民币 审计类型:未经审计
                      项目                            本期金额(1-3 月)  上期金额(1-3 月)
一、营业收入                                             595,734,024.24       564,878,873.63
  减:营业成本                                           168,321,654.36       153,300,438.60
       营业税金及附加                                       9,749,506.92        9,181,391.84
       销售费用                                          225,653,555.37       214,257,100.58
       管理费用                                            86,825,634.37       82,149,744.31
       财务费用                                             9,364,338.64        9,466,688.16
       资产减值损失                                      -12,861,337.83            504,102.52
  加:公允价值变动收益(损失以“-”号填
列)
       投资收益(损失以“-”号填列)
       其中:对联营企业和合营企业的投资收

二、营业利润(亏损以“-”号填列)                       108,680,672.41        96,019,407.62
  加:营业外收入                                            2,704,000.00        2,150,000.00
       其中:非流动资产处置利得
  减:营业外支出                                               17,221.57
       其中:非流动资产处置损失                                17,221.57
三、利润总额(亏损总额以“-”号填列)                   111,367,450.84        98,169,407.62
     减:所得税费用                                        16,705,117.63       14,649,795.77
四、净利润(净亏损以“-”号填列)                         94,662,333.21       83,519,611.85
五、其他综合收益的税后净额
  (一)以后不能重分类进损益的其他综合收

    1.重新计量设定受益计划净负债或净资产
的变动
    2.权益法下在被投资单位不能重分类进损
益的其他综合收益中享有的份额
  (二)以后将重分类进损益的其他综合收益
    1.权益法下在被投资单位以后将重分类进
损益的其他综合收益中享有的份额
     2.可供出售金融资产公允价值变动损益
    3.持有至到期投资重分类为可供出售金融
资产损益
     4.现金流量套期损益的有效部分
     5.外币财务报表折算差额
     6.其他
六、综合收益总额                                           94,662,333.21       83,519,611.85

                                             17 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                2016 年第一季度报告



七、每股收益:
    (一)基本每股收益(元/股)
    (二)稀释每股收益(元/股)



法定代表人:肖伟            主管会计工作负责人:尹洪刚   会计机构负责人:江锁成




                                            18 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                           2016 年第一季度报告



                                        合并现金流量表
                                        2016 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                                   单位:元 币种:人民币 审计类型:未经审计
                 项目                         本期金额(1-3月)         上期金额(1-3月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                        880,423,300.58         658,802,879.63
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额
  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当
期损益的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还
  收到其他与经营活动有关的现金                         47,036,538.54          45,571,352.88
    经营活动现金流入小计                              927,459,839.12         704,374,232.51
  购买商品、接受劳务支付的现金                        232,383,724.91          51,681,445.48
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                       91,983,261.54          80,600,252.14
  支付的各项税费                                      127,229,612.25         115,156,979.37
  支付其他与经营活动有关的现金                        338,273,917.42         319,298,314.38
    经营活动现金流出小计                              789,870,516.12         566,736,991.37
      经营活动产生的现金流量净额                      137,589,323.00         137,637,241.14
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期资
                                                            1,270.00
产收回的现金净额
  处置子公司及其他营业单位收到的现
金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                    1,270.00                     0.00
  购建固定资产、无形资产和其他长期资                  173,088,698.40         147,592,066.84

                                            19 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                              2016 年第一季度报告



产支付的现金
  投资支付的现金                                        4,650,000.00
  质押贷款净增加额
  取得子公司及其他营业单位支付的现
金净额
  支付其他与投资活动有关的现金                                                        37,407.23
    投资活动现金流出小计                              177,738,698.40            147,629,474.07
      投资活动产生的现金流量净额                   -177,737,428.40             -147,629,474.07
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  其中:子公司吸收少数股东投资收到的
现金
  取得借款收到的现金                                  686,000,000.00            102,474,286.67
  发行债券收到的现金
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                              686,000,000.00            102,474,286.67
  偿还债务支付的现金                                  651,195,693.98            291,623,333.33
  分配股利、利润或偿付利息支付的现金                    6,758,994.83             12,713,172.22
  其中:子公司支付给少数股东的股利、
利润
  支付其他与筹资活动有关的现金
    筹资活动现金流出小计                              657,954,688.81            304,336,505.55
      筹资活动产生的现金流量净额                      28,045,311.19            -201,862,218.88
四、汇率变动对现金及现金等价物的影响                       -1,204.47                   9,731.47
五、现金及现金等价物净增加额                          -12,103,998.68           -211,844,720.34
  加:期初现金及现金等价物余额                        221,716,287.08            553,542,219.35
六、期末现金及现金等价物余额                          209,612,288.40            341,697,499.01



法定代表人:肖伟            主管会计工作负责人:尹洪刚                 会计机构负责人:江锁成




                                            20 / 22
    江苏康缘药业股份有限公司(股票代码:600557)                       2016 年第一季度报告



                                  母公司现金流量表
                                    2016 年 1—3 月
编制单位:江苏康缘药业股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计
                 项目                              本期金额             上期金额
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                        773,207,471.07     590,468,590.06
  收到的税费返还
  收到其他与经营活动有关的现金                         18,213,486.19      23,271,999.79
    经营活动现金流入小计                              791,420,957.26     613,740,589.85
  购买商品、接受劳务支付的现金                        212,208,828.39      59,860,589.98
  支付给职工以及为职工支付的现金                       73,807,475.39      62,355,461.44
  支付的各项税费                                      108,275,709.54      96,978,582.61
  支付其他与经营活动有关的现金                        289,483,242.07     253,507,670.53
    经营活动现金流出小计                              683,775,255.39     472,702,304.56
      经营活动产生的现金流量净额                      107,645,701.87     141,038,285.29
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期资
                                                              240.00                 0.00
产收回的现金净额
  处置子公司及其他营业单位收到的现
金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                      240.00                 0.00
  购建固定资产、无形资产和其他长期资
                                                      146,708,545.01     136,008,975.37
产支付的现金
  投资支付的现金
  取得子公司及其他营业单位支付的现
金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                              146,708,545.01     136,008,975.37
      投资活动产生的现金流量净额                   -146,708,305.01      -136,008,975.37
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                                  536,000,000.00      67,474,286.67
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                              536,000,000.00      67,474,286.67
  偿还债务支付的现金                                  501,195,693.98     259,623,333.33
  分配股利、利润或偿付利息支付的现金                    4,944,550.38       8,603,273.31
  支付其他与筹资活动有关的现金
    筹资活动现金流出小计                              506,140,244.36     268,226,606.64

                                            21 / 22
      江苏康缘药业股份有限公司(股票代码:600557)                              2016 年第一季度报告



        筹资活动产生的现金流量净额                      29,859,755.64            -200,752,319.97
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                             -9,202,847.50           -195,723,010.05
  加:期初现金及现金等价物余额                          164,310,146.60            480,293,517.16
六、期末现金及现金等价物余额                            155,107,299.10            284,570,507.11



法定代表人:肖伟              主管会计工作负责人:尹洪刚                 会计机构负责人:江锁成


4.2    审计报告

□适用 √不适用




                                              22 / 22